Patents by Inventor Michael Matthew Miller

Michael Matthew Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Broadband adaptive lens assembly for augmented reality display
    Patent number: 11960165
    Abstract: A display device comprises a waveguide configured to guide light in a lateral direction parallel to an output surface of the waveguide. The waveguide is further configured to outcouple the guided light through the output surface. The display device additionally comprises a broadband adaptive lens assembly configured to incouple and to diffract therethrough the outcoupled light from the waveguide. The broadband adaptive lens assembly comprises a first waveplate lens comprising a liquid crystal (LC) layer arranged such that the waveplate lens has birefringence (?n) that varies in a radially outward direction from a central region of the first waveplate lens and configured to diffract the outcoupled light at a diffraction efficiency greater than 90% within a wavelength range including at least 450 nm to 630 nm. The broadband adaptive lens assembly is configured to be selectively switched between a plurality of states having different optical powers.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: April 16, 2024
    Assignee: MAGIC LEAP, INC.
    Inventors: Chulwoo Oh, Ravi Kumar Komanduri, Roy Matthew Patterson, Charles Scott Carden, Michael Nevin Miller, Vikramjit Singh
  • Augmented reality display having liquid crystal variable focus element and roll-to-roll method and apparatus for forming the same
    Patent number: 11921290
    Abstract: A display device includes a waveguide assembly comprising a waveguide configured to outcouple light out of a major surface of the waveguide to form an image in the eyes of a user. An adaptive lens assembly has a major surface facing the output surface and a waveplate lens and a switchable waveplate assembly. The switchable waveplate assembly includes quarter-wave plates on opposing sides of a switchable liquid crystal layer, and electrodes on the quarter-wave plates in the volume between the quarter-wave plates. The electrodes can selectively establish an electric field and may serve as an alignment structure for molecules of the liquid crystal layer. Portions of the adaptive lens assembly may be manufactured by roll-to-roll processing in which a substrate roll is unwound, and alignment layers and liquid crystal layers are formed on the substrate as it moves towards a second roller, to be wound on that second roller.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: March 5, 2024
    Assignee: Magic Leap, Inc.
    Inventors: Roy Matthew Patterson, Chulwoo Oh, Ravi Kumar Komanduri, Charles Scott Carden, Michael Nevin Miller, Vikramjit Singh, Shuqiang Yang
  • Cyclic peptide immunomodulators
    Patent number: 11492375
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, II, Martin Patrick Allen, Ling Li
  • IMMUNOMODULATORS
    Publication number: 20200291069
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 2, 2018
    Publication date: September 17, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michael Matthew MILLER, II, Martin Patrick ALLEN, Ling LI
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 10538555
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 21, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
  • Immunomodulators
    Patent number: 10450347
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: October 22, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Immunomodulators
    Patent number: 10358463
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Michael S. Bowsher, Eric P. Gillis, Eric Mull, Qian Zhao, Li-Qiang Sun, David R. Langley, Paul Michael Scola
  • Immunomodulators
    Patent number: 10143746
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
  • Immunomodulators
    Patent number: 9944678
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Eric P. Gillis, Michael Matthew Miller, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9879046
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20170369530
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 9, 2017
    Publication date: December 28, 2017
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
    Patent number: 9850283
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20170283462
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 5, 2017
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • IMMUNOMODULATORS
    Publication number: 20170283463
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Michael S. Bowsher, Eric P. Gillis, Eric Mull, Qian Zhao, Li-Qiang Sun, David R. Langley, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20170260237
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: September 11, 2014
    Publication date: September 14, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A.M. Cornelius
  • IMMUNOMODULATORS
    Publication number: 20170252432
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 1, 2017
    Publication date: September 7, 2017
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael
  • Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions
    Publication number: 20160340391
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 24, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160222060
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Immunomodulators
    Publication number: 20160176928
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric P. Gillis, Michael Matthew Miller, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
    Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola